Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Open Label Phase 1/2 Trial of Tisotumab Vedotin in Japanese Subjects with Advanced Solid Malignancies
jRCT2080224570Phase 2Completed
- Sponsor
- Genmab
- Start
- Feb 2019
- Modality
- Cytotoxic ADCs → Antibody-Drug Conjugates (ADCs) → Antibody Conjugates → Antibody-Based Therapeutics, Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label trial of tisotumab vedotin in Nonhematologic neoplasms and Cervical Cancer (CC) (2 arms), sponsored by Genmab. Started Feb 2019; status: completed.
02
Drugs
tisotumab vedotin
03
Conditions
Nonhematologic neoplasmsCervical Cancer (CC)
Beyond the preview
Go deeper on jRCT2080224570.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2080224570.